TDO2
TDO2 does the same job as IDO1, breaking down tryptophan into kynurenine, which quietens T cells. It is one reason IDO1 inhibitors alone may not have been enough; no TDO2 drug has reached late trials.
Overview
TDO2 (chromosome 4q32.1) is a haem-dependent dioxygenase that catalyses the oxidative cleavage of the L-tryptophan pyrrole ring, converting it to N-formyl-L-kynurenine (UniProt P48775). IDO1 and TDO2 catalyse the commitment step of the kynurenine pathway; kynurenine activates the aryl hydrocarbon receptor, generating immune-tolerant dendritic cells and regulatory T cells and a tumour microenvironment defective at recognising cancer cells (Cheong and Sun 2018, Trends Pharmacol Sci). No TDO2-selective agent was found in ClinicalTrials.gov under the names the corpus knows.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TDO2 does the same job as IDO1, breaking down tryptophan into kynurenine, which quietens T cells. It is one reason IDO1 inhibitors alone may not have been enough; no TDO2 drug has reached late trials.
- 1 · What it is
TDO2 does the same job as IDO1, breaking down tryptophan into kynurenine, which quietens T cells. It is one reason IDO1 inhibitors alone may not have been enough; no TDO2 drug has reached late trials.
- 2 · What goes wrong in cancer
The liver-type tryptophan dioxygenase; UniProt records no tissue distribution for the human protein, so none is claimed here.
- 3 · How drugs use it
No product in this corpus aims at TDO2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:11708 (approved symbol, name, aliases and cross-references); UniProt P48775 (protein name, function and tissue specificity)
Biology
The liver-type tryptophan dioxygenase; UniProt records no tissue distribution for the human protein, so none is claimed here.
- Not recorded by UniProt for the human protein
Notes
top- Prevalence not recorded: HGNC and UniProt carry no positivity rates.
Latest papers
topQuery for this target: (TITLE:"TDO2" OR ABSTRACT:"TDO2" OR TITLE:"tryptophan 2,3-dioxygenase" OR ABSTRACT:"tryptophan 2,3-dioxygenase" OR TITLE:"TDO" OR ABSTRACT:"TDO") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TDO2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetLILRB1 (ILT2)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD39 (ENTPD1)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetHHLA2 (B7-H7)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetGITR (TNFRSF18)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD27
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetAdenosine A2A receptor (ADORA2A)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetHLA-E
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetLILRB2 (ILT4)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.